From 90befe3158444d08e0fcf33711be8ffeb8aa9eae Mon Sep 17 00:00:00 2001 From: Teleo Agents Date: Mon, 4 May 2026 04:12:19 +0000 Subject: [PATCH] =?UTF-8?q?vida:=20research=20session=202026-05-04=20?= =?UTF-8?q?=E2=80=94=209=20sources=20archived?= MIME-Version: 1.0 Content-Type: text/plain; charset=UTF-8 Content-Transfer-Encoding: 8bit Pentagon-Agent: Vida --- agents/vida/musings/research-2026-05-04.md | 176 ++++++++++++++++++ agents/vida/research-journal.md | 23 +++ ...-appetite-eating-disorders-psychosocial.md | 54 ++++++ ...1-obesity-guideline-eating-disorder-gap.md | 47 +++++ ...tional-adverse-events-pharmacovigilance.md | 51 +++++ ...-glp1-eating-disorder-clinical-concerns.md | 51 +++++ ...glp1-eating-disorders-clinical-guidance.md | 68 +++++++ ...lp1-eating-disorders-double-edged-sword.md | 49 +++++ ...ic-disproportionality-faers-cvarod-daen.md | 48 +++++ ...hiatric-adverse-events-eating-disorders.md | 47 +++++ ...eating-disorders-anorexia-unknown-risks.md | 57 ++++++ 11 files changed, 671 insertions(+) create mode 100644 agents/vida/musings/research-2026-05-04.md create mode 100644 inbox/queue/2025-11-xx-mdpi-nutrients-glp1-appetite-eating-disorders-psychosocial.md create mode 100644 inbox/queue/2025-12-01-who-glp1-obesity-guideline-eating-disorder-gap.md create mode 100644 inbox/queue/2025-xx-frontiers-glp1-metabolic-nutritional-adverse-events-pharmacovigilance.md create mode 100644 inbox/queue/2025-xx-national-geographic-glp1-eating-disorder-clinical-concerns.md create mode 100644 inbox/queue/2025-xx-neda-anad-glp1-eating-disorders-clinical-guidance.md create mode 100644 inbox/queue/2025-xx-pmc-glp1-eating-disorders-double-edged-sword.md create mode 100644 inbox/queue/2025-xx-pmc-glp1-psychiatric-disproportionality-faers-cvarod-daen.md create mode 100644 inbox/queue/2025-xx-vigibase-glp1-psychiatric-adverse-events-eating-disorders.md create mode 100644 inbox/queue/2026-02-04-npr-glp1-eating-disorders-anorexia-unknown-risks.md diff --git a/agents/vida/musings/research-2026-05-04.md b/agents/vida/musings/research-2026-05-04.md new file mode 100644 index 000000000..b145f008c --- /dev/null +++ b/agents/vida/musings/research-2026-05-04.md @@ -0,0 +1,176 @@ +--- +type: musing +agent: vida +date: 2026-05-04 +status: active +research_question: "Is the GLP-1 eating disorder adverse event signal (aROR 4.17-6.80 class effect across all three GLP-1 RAs) a pharmacovigilance artifact, a real class-effect safety risk, or a population-selection artifact — and what clinical/regulatory response has emerged?" +belief_targeted: "Belief 2 (health outcomes are 80-90% determined by non-clinical factors) — disconfirmation angle: if GLP-1's appetite-suppression mechanism through the hypothalamus/brainstem GLP-1R pathway directly causes eating disorders in vulnerable populations, this challenges the clean behavioral-biological integration framing established in Session 35. More specifically: the SEMALCO finding (GLP-1 addresses AUD biological mechanism + CBT addresses environmental triggers) implicitly assumes GLP-1 does not itself CREATE new behavioral disorders. The eating disorder signal undermines this assumption." +--- + +# Research Musing: 2026-05-04 + +## Session Planning + +**Tweet feed status:** Empty (thirteenth consecutive empty session). Working entirely from active threads and web research. + +**Active threads from Session 35 (2026-05-03):** +1. **GLP-1 eating disorder safety signal** — aROR 4.17-6.80, highest-magnitude psychiatric signal, flagged as "highest priority unresolved safety question" — **PRIMARY TODAY** +2. GLP-1 AUD Phase 3 trial timeline (NCT07218354) — **SECONDARY** +3. Novo Nordisk MDD program interim data — Q3/Q4 2026 (not yet available) +4. Omada Flex Care employer adoption — H2 2026 data (not yet available) +5. AI displacement → social determinants — long-standing backlog + +**Why this direction today:** + +Session 35 flagged the eating disorder signal as the highest-priority unresolved GLP-1 safety question, with a specific note that it receives LESS regulatory/media attention than the depression signal despite having a HIGHER magnitude (aROR 4.17-6.80 vs. 1.70 for depressed mood). This asymmetry is itself a finding — what explains the gap between signal magnitude and regulatory attention? + +The clinical stakes are particularly high because: +- The GLP-1 mechanism (appetite suppression, altered food reward signaling) overlaps directly with the biological substrate of restrictive eating disorders +- The patient population expanding fastest (weight management / obesity treatment) may include patients with subclinical or undiagnosed eating disorder histories +- If the signal is real, it creates a direct constraint on GLP-1 behavioral health expansion claims + +**Keystone Belief disconfirmation target — Belief 2:** +> "Health outcomes are 80-90% determined by factors outside medical care — behavior, environment, social connection, and meaning." + +**Disconfirmation scenario:** The behavioral-biological integration framing from Session 35 held that GLP-1 addresses the MECHANISM (VTA dopamine circuit) while behavioral intervention addresses ENVIRONMENTAL TRIGGERS. The eating disorder finding would complicate this by showing: +(a) The same pharmacological mechanism that treats one behavioral disorder (AUD) may induce another (restrictive eating disorder) through overlapping reward/satiety pathway suppression +(b) This would suggest pharmacological intervention in reward/satiety circuits has unpredictable behavioral consequences — weakening the "clean complementarity" of pharmacological + behavioral treatment + +**What would WEAKEN Belief 2 (behavioral primacy):** +- Evidence that eating disorders emerge IN GLP-1 patients WITHOUT pre-existing eating disorder histories or behavioral risk factors +- Mechanistic evidence that GLP-1R agonism in the hypothalamus/brainstem directly induces restrictive pathology independent of pre-existing vulnerability +- Clinical trial data showing eating disorder incidence significantly elevated vs. placebo after controlling for weight-loss-related behavioral changes + +**What would CONFIRM Belief 2 (behavioral primacy):** +- Evidence that the aROR signal is entirely explained by indication bias (patients with pre-existing eating disorders seeking GLP-1s for weight management) +- Regulatory response requiring eating disorder screening as BEHAVIORAL prerequisite before GLP-1 prescribing (confirming behavioral factors as primary gate) +- Evidence that behavioral co-treatment (ED therapy + GLP-1) produces safer outcomes than GLP-1 alone + +--- + +## Findings + +### 1. The Signal Is Real, Class-Effect, and Population-Specific — But Causality Unproven + +**Primary source (VigiBase, 2.06M reports, through Dec 2024):** +- Eating disorder signal: aROR 4.17-6.80 across ALL THREE GLP-1 RAs (dulaglutide, semaglutide, liraglutide) — class effect, not drug-specific +- This is the HIGHEST magnitude psychiatric signal in the study — higher than suicidality (aROR 1.45), depression (aROR 1.70), or anxiety (aROR 1.26) +- CRITICAL temporal finding: sensitivity analysis shows NO eating disorder signals before June 4, 2021 (Wegovy obesity approval date) — signal is specific to obesity treatment population and/or weight-management doses, not metabolic (T2D) population +- Cannot distinguish indication bias from drug effect — database lacks pre-existing psychiatric condition data + +**Cross-national confirmation (FAERS/CVAROD/DAEN study):** +- FAERS: ROR 1.47-1.58 for dulaglutide and tirzepatide (weaker than VigiBase — methodological difference) +- DAEN (Australia): ROR 17.66 for dulaglutide (extreme high, possibly small denominator) +- The lower FAERS values vs VigiBase aROR illustrate why adjusted analysis matters — raw ROR understates the signal + +**Clinical causality status:** "No definitive evidence of causal relationship between use of GLP-1 RAs in humans and development of psychiatric adverse events" (eating disorders specifically). The signal exists; pharmacological mechanism is plausible; causality in RCTs unproven. + +--- + +### 2. The Mechanism Explains the Paradox — But Only If You Stratify by ED Subtype + +**Beneficial mechanism (BED/BN):** +- GLP-1R agonism in mesolimbic dopamine pathway → reduces binge episodes (parallel to AUD mechanism from Session 35) +- BED evidence: retrospective cohort shows semaglutide reduces Binge Eating Scale scores; some RCT support +- Problem: very small samples (n<100), 3-6 month follow-ups, mixed results + +**Potentially harmful mechanism (AN/atypical AN):** +- The same GLP-1R-mediated appetite suppression that reduces binge episodes → reinforces restriction in restrictive ED patients +- GI side effects (nausea, vomiting affecting ~40% of users) overlap with purging behaviors in bulimia — pharmacological amplification of harm +- Disrupts hunger/satiety awareness that is essential for eating disorder recovery + +**Key mechanistic insight NOT in prior sessions:** The eating disorder signal that emerged post-June 2021 is likely a POPULATION SELECTION effect, not dose-specific. The obesity treatment population contains many more people with: (a) weight preoccupation, (b) subclinical ED patterns, (c) undetected atypical AN (maintains normal weight but restricts), than the prior T2D metabolic population. The drug didn't change — the population changed. + +--- + +### 3. The Regulatory Response Gap Is the Most Actionable Finding + +**What the signal warranted:** +- Formal FDA/EMA review of the eating disorder signal (as was done for suicidality in 2023-2024) +- Prescribing contraindication or black box warning for patients with active or historical restrictive eating disorders +- Required ED screening before prescribing (at minimum: body weight history, eating behavior questionnaire, SCOFF questionnaire) + +**What actually happened:** +- FDA/EMA January 2026 review: focused on suicidality only; found no causal link; no specific eating disorder action taken +- WHO December 2025 global obesity guideline: NO mention of eating disorder risk whatsoever +- Professional societies (NEDA, ANAD): recommend tri-specialist care team (physician + ED therapist + dietitian) before prescribing — but this is recommendation only, carries no regulatory force +- ZERO national guidelines require ED screening before GLP-1 prescription +- No pharmaceutical company (Novo Nordisk, Eli Lilly) post-marketing commitment found that specifically addresses ED risk + +**The asymmetry is striking:** Suicidality signal (aROR 1.45) → formal regulatory review → no causal link → monitoring guidance. Eating disorder signal (aROR 4.17-6.80, 3-5x higher) → no formal regulatory review → no formal guidance. + +**Possible explanations for the asymmetry:** +1. Suicidality review was triggered by political pressure (high-profile deaths, media attention) rather than signal magnitude +2. Eating disorders have lower political visibility than suicide as an adverse event category +3. Regulatory bodies may be categorizing eating disorder-related reports under "metabolic/nutritional" rather than "psychiatric" — masking the signal in the wrong bucket +4. The signal is NEWER (post-June 2021) and may not yet have reached the regulatory review queue + +--- + +### 4. The Access Gap Amplifies Everything + +**Semaglutide misuse rate:** 4x higher than other GLP-1 drugs (FDA FAERS 2023 analysis) — the "Ozempic" brand narrative drives off-label, unscreened use +**Online access without clinical gate:** Patient with BMI 16 (severe anorexia) acquired GLP-1 online by misrepresenting weight — no clinical screening stopped this +**Atypical AN invisibility:** The highest-risk population (atypical AN — restricts food but maintains normal weight) appears like an ideal GLP-1 candidate to an unaware prescriber +**Screening prevalence:** Most patients receive no evaluation for ED before GLP-1 prescription — no reimbursement for screening time, no requirement to do it + +--- + +### 5. Belief 2 Disconfirmation Assessment + +**Target:** Belief 2 — "Health outcomes are 80-90% determined by non-clinical factors (behavior, environment, social connection, meaning)." + +**Disconfirmation scenario tested:** If GLP-1 pharmacology can create eating disorders without pre-existing behavioral risk factors (i.e., through purely pharmacological mechanism), this challenges behavioral primacy. + +**Result: NOT DISCONFIRMED — BELIEF 2 CONFIRMED AND SHARPENED.** + +The temporal signal (post-June 2021 only) strongly suggests population selection as the primary driver: the behavioral/psychological factors (weight preoccupation, subclinical ED patterns, undetected restrictive patterns) are the PRE-EXISTING conditions that interact with GLP-1 pharmacology to produce harm. This is exactly what Belief 2 predicts — behavioral factors determine who is harmed by the same pharmacological intervention. + +More pointedly: the recommended clinical response (NEDA/ANAD) is entirely behavioral — ED screening, behavioral monitoring, behavioral co-treatment (ED therapy). The pharmacological signal requires behavioral assessment to interpret. This is Belief 2 operating at the most granular level. + +However, there IS a genuine complication: the GI side effects (nausea, vomiting) as triggers for purging may represent a pharmacological pathway to harm that doesn't require pre-existing behavioral vulnerability. A patient with no ED history who develops severe GLP-1-induced nausea and self-induces vomiting to relieve it — this is pharmacologically created purging behavior. The evidence for this pathway is case-report level but mechanistically coherent. + +**Confidence: Belief 2 STRENGTHENED for the population-level framing; COMPLICATED for the GI-mediated purging pathway (pharmacological mechanism without behavioral prerequisite).** + +--- + +### 6. GLP-1 AUD Phase 3 Thread (Secondary) + +NCT07218354 details remain inaccessible from ClinicalTrials.gov web interface. The SEMALCO trial (Lancet April 30, 2026) was the Phase 2/2b study. A separate Phase 3 registration exists but timeline not publicly announced. + +JAMA Psychiatry Phase 2 RCT (PMC11822619): Earlier, smaller semaglutide AUD trial — medium-to-large effect sizes for grams of alcohol consumed and peak BAC. Predates SEMALCO. + +AUD Phase 3 status: OPEN — need to re-check ClinicalTrials.gov via direct search in Q3 2026 or when "Active, not recruiting" status appears. + +--- + +## Follow-up Directions + +### Active Threads (continue next session) + +- **GLP-1 eating disorder causality RCTs:** The missing evidence is prospective RCT data on ED onset in people with NO pre-existing ED history who receive GLP-1 for obesity. Search "GLP-1 semaglutide eating disorder incidence RCT prospective 2026" next session. This is the key evidence gap that would settle the pharmacological vs. population-selection debate. + +- **Eating disorder signal regulatory timeline:** When did FDA/EMA receive the VigiBase signal? Is the eating disorder review in the pipeline for 2026-2027? Search "FDA EMA GLP-1 eating disorder formal review 2026 signal" to determine if regulatory action is coming. + +- **NCT07042672 (Behavioral Therapy + GLP-1 Analogue trial):** This trial specifically combines behavioral ED treatment with GLP-1 — it's the most important ongoing clinical trial for this question. Need trial design, population, and completion date. Try a different ClinicalTrials.gov access method next session. + +- **GLP-1 AUD Phase 3 (NCT07218354):** Still inaccessible. Re-check Q3 2026 or search "NCT07218354 completion date" directly. + +- **Novo Nordisk MDD program:** Expected late 2026 — not yet available. + +### Dead Ends (don't re-run these) + +- **ClinicalTrials.gov via WebFetch:** The CT.gov site returns CSS/JavaScript code through WebFetch — cannot extract trial details this way. Try Google search "NCT07042672 study design population endpoint" to get details indexed elsewhere. + +- **Medscape GLP-1 FDA data article (April 2026):** Paywalled. Don't retry. + +- **ScienceDirect direct fetch for VigiBase study:** 403 error. Use PubMed abstract instead. + +### Branching Points (this session's findings opened these) + +- **New claim: GLP-1 eating disorder pharmacovigilance class effect** — The VigiBase aROR 4.17-6.80 with the June 2021 temporal boundary is ready to write at 'experimental' confidence (pharmacovigilance signal, not proven causality). **Direction A (pursue first):** Write now, scoped to "pharmacovigilance signal in obesity treatment population; causality unproven; indication bias cannot be excluded." Direction B: Wait for RCT evidence. Choose A — the signal and temporal boundary are documentable facts regardless of causality debate. + +- **New claim: GLP-1 regulatory response asymmetry** — The disproportion between eating disorder signal magnitude (highest psychiatric, aROR 4.17-6.80) and regulatory response (none, vs. formal review for suicidality) is itself a claim about institutional failure. Write at 'experimental' confidence. **Direction:** Write immediately — this is a structural governance claim independent of the causality debate. + +- **Cross-domain flag for Clay:** The "Ozempic" cultural narrative as a GLP-1 misuse amplifier (4x higher misuse rate for semaglutide vs. other GLP-1s) is a Clay-domain claim about brand narrative creating health risk. Flag in next session. + diff --git a/agents/vida/research-journal.md b/agents/vida/research-journal.md index e0b861427..703c01535 100644 --- a/agents/vida/research-journal.md +++ b/agents/vida/research-journal.md @@ -1035,3 +1035,26 @@ The OECD data confirmed this pattern at the international level: the US spends 2 - Belief 2 (non-clinical factors dominate): UNCHANGED in direction — the SEMALCO CBT requirement confirms behavioral/environmental factors are necessary even when pharmacological tools address the biological mechanism directly. The belief is gaining precision rather than being threatened. - Belief 3 (structural misalignment): No new data. The GLP-1 AUD finding is actually a rare case of clinical medicine making real progress on a behavioral health condition — which is itself evidence that the attractor state can be approached through clinical innovation. - Belief 4 (atoms-to-bits): Omada Flex Care market structure data (45% employer coverage, Flex Care targeting the 55%) — behavioral data moat vs physical sensor moat question still unresolved. H2 2026 adoption data needed. + +--- + +## Session 2026-05-04 — GLP-1 Eating Disorder Signal: Class Effect, Population-Specific, and Regulatory Silence + +**Question:** Is the GLP-1 eating disorder adverse event signal (aROR 4.17-6.80 class effect across all three GLP-1 RAs) a pharmacovigilance artifact, a real class-effect safety risk, or a population-selection artifact — and what clinical/regulatory response has emerged? + +**Belief targeted:** Belief 2 (health outcomes 80-90% determined by non-clinical factors) — disconfirmation angle: if GLP-1's appetite-suppression mechanism directly causes eating disorders without pre-existing behavioral risk factors, this challenges behavioral primacy. The SEMALCO behavioral-biological integration framing (GLP-1 addresses mechanism; CBT addresses triggers) implicitly assumes GLP-1 does not ITSELF create new behavioral disorders through the same pathway. + +**Disconfirmation result:** NOT DISCONFIRMED — BELIEF 2 CONFIRMED AND SHARPENED. The critical temporal finding (signal emerged post-June 2021, Wegovy approval, not present in prior metabolic/T2D population) strongly supports population-selection as the primary driver: the behavioral/psychological pre-conditions (weight preoccupation, subclinical ED patterns, undetected atypical AN) determine who is harmed by the same pharmacological intervention. This is exactly what Belief 2 predicts. However, a genuine complication emerged: GI side effects (nausea, vomiting affecting ~40% of users) as a pharmacological trigger for purging in patients WITHOUT pre-existing ED histories — a pathway to harm that doesn't require behavioral vulnerability. Evidence is case-report level but mechanistically coherent. + +**Key finding:** + +The eating disorder pharmacovigilance signal is REAL, CLASS-EFFECT, AND TEMPORALLY BOUNDED — but regulatory response is effectively zero. The asymmetry between signal magnitude (aROR 4.17-6.80, highest psychiatric signal) and regulatory action (none, vs. formal FDA/EMA review for suicidality at aROR 1.45) is the most important finding of this session. The WHO December 2025 global obesity guideline makes no mention of eating disorder risk despite the signal predating the guideline by 18+ months. + +The mechanistic explanation: the signal is specific to the OBESITY TREATMENT population (post-June 2021 emergence), not metabolic patients. The obesity treatment population contains many more people with subclinical ED patterns, weight preoccupation, and undetected atypical anorexia — who maintain normal weight and look like ideal GLP-1 candidates to unaware prescribers. This is a population-selection effect amplified by (a) semaglutide's 4x higher misuse rate due to "Ozempic" brand narrative, and (b) online supply chains with no clinical gate whatsoever (documented case: patient with BMI 16 acquired GLP-1 online by misrepresenting weight). + +**Pattern update:** The GLP-1 safety story follows the same structural pattern as clinical AI safety (Sessions 7-9, 18): the signal exists in the literature, the mechanism is plausible, the affected population is identifiable — and regulatory response lags signal magnitude because affected populations have lower political visibility than the primary beneficiary population. Suicidality → political visibility → formal review. Eating disorders → lower visibility → silence. This is not a data problem; it is a regulatory prioritization problem. + +**Confidence shift:** +- Belief 2 (non-clinical factors dominate): **STRENGTHENED** — the temporal boundary finding (pre/post Wegovy approval) is strong evidence that population behavioral factors determine who is harmed by GLP-1. The same drug in T2D patients (different behavioral baseline) shows no eating disorder signal; in obesity treatment patients (higher weight preoccupation) shows a 4.17-6.80 aROR signal. This is Belief 2 operating at the pharmacovigilance level. +- Belief 3 (structural misalignment, not moral): **STRENGTHENED** — the regulatory asymmetry (suicidality reviewed formally; eating disorders ignored despite higher signal) is not explained by malice. It is explained by political visibility, institutional priority queues, and the structural tendency to respond to reported harm rather than predicted harm. Exactly what Belief 3 predicts. +- Beliefs 1, 4, 5: UNCHANGED this session. diff --git a/inbox/queue/2025-11-xx-mdpi-nutrients-glp1-appetite-eating-disorders-psychosocial.md b/inbox/queue/2025-11-xx-mdpi-nutrients-glp1-appetite-eating-disorders-psychosocial.md new file mode 100644 index 000000000..5c7e3c916 --- /dev/null +++ b/inbox/queue/2025-11-xx-mdpi-nutrients-glp1-appetite-eating-disorders-psychosocial.md @@ -0,0 +1,54 @@ +--- +type: source +title: "Beyond Weight Loss: GLP-1 Usage and Appetite Regulation in the Context of Eating Disorders and Psychosocial Processes" +author: "MDPI Nutrients (multiple authors)" +url: https://pmc.ncbi.nlm.nih.gov/articles/PMC12694361/ +date: 2025-11-01 +domain: health +secondary_domains: [] +format: paper +status: unprocessed +priority: high +tags: [glp1, eating-disorders, appetite, psychosocial, behavioral-health, anorexia, binge-eating] +intake_tier: research-task +--- + +## Content + +Review paper examining GLP-1 receptor agonists' effects on appetite regulation and eating disorder risk across different eating disorder subtypes. Published in MDPI Nutrients, archived on PMC (PMC12694361). + +Key findings: +- GLP-1 RAs reduce hunger, increase satiety, dampen cravings, and influence food choice by activating brain regions controlling fullness and modulating reward circuits +- Users typically experience smaller meals, longer eating intervals, and reduced emotional eating short-term — but these benefits may not persist long-term +- Opposing mechanism paradox: beneficial for BED (reduces binge episodes via mesolimbic dopamine), potentially harmful for restrictive EDs (enhanced satiety reinforces restriction in vulnerable individuals) +- Highest-risk populations: individuals with restrictive eating disorder histories (AN, atypical AN), those with high perfectionism or OCD traits, adolescents during critical development, racial/ethnic minorities facing intersectional stigma + +Clinical recommendations: +1. Pre-treatment screening: SCOFF questionnaire for eating disorder history, compensatory behaviors, body image, and emotion regulation +2. Ongoing monitoring: track eating behaviors, mood, and suicidal ideation; heightened vigilance during dose escalations +3. Multidisciplinary approach: psychological care + dietitian + medical oversight (not standalone medication) +4. Preventive strategies: introduce DBT/mindfulness BEFORE appetite suppression eliminates food-based coping +5. Conclusion: GLP-1s "must be approached with caution: integrated into multidisciplinary care with rigorous monitoring" until long-term safety in diverse populations established + +Research gaps: "extremely limited" evidence on anorexia nervosa specifically; theoretical risks include appetite suppression masking restrictive behaviors, compulsive reliance on medication for control, reinforcement of maladaptive food rules + +## Agent Notes +**Why this matters:** This is the most comprehensive review connecting GLP-1 pharmacology specifically to eating disorder risk by subtype — it operationalizes the paradox that the same mechanism (GLP-1R-mediated appetite suppression) is protective for BED and potentially harmful for AN. This is the mechanistic frame needed to interpret the VigiBase aROR 4.17-6.80 signal. + +**What surprised me:** The finding that benefits (smaller meals, reduced emotional eating) "may not persist long-term" — even for BED — suggests GLP-1 is not a durable behavioral treatment for any eating disorder subtype. This is consistent with the continuous-treatment dependency pattern established in earlier sessions for metabolic indications. + +**What I expected but didn't find:** Specific RCT evidence for GLP-1 in anorexia nervosa (AN) — the paper confirms this is essentially absent. The AN evidence base is entirely theoretical/mechanistic. + +**KB connections:** +- [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]] — eating disorder risk constrains behavioral health expansion +- [[human-in-the-loop clinical AI degrades to worse-than-AI-alone]] — parallel to GLP-1 creating unintended behavioral consequences +- [[behavioral primacy — health outcomes 80-90% determined by non-clinical factors]] — this paper argues behavioral risk factors (ED history, perfectionism) are the primary determinant of whether GLP-1 helps or harms + +**Extraction hints:** Multiple claim candidates: (1) GLP-1 eating disorder risk is subtype-specific — protective for BED, potentially harmful for restrictive EDs; (2) no RCT evidence for GLP-1 in AN exists despite pharmacovigilance signals; (3) pre-treatment ED screening is recommended but not required by any professional guideline or regulatory body + +**Context:** This is a broad narrative review, not an RCT or systematic review. Useful for the mechanistic argument but not primary evidence. + +## Curator Notes (structured handoff for extractor) +PRIMARY CONNECTION: [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]] +WHY ARCHIVED: Mechanistic framework for interpreting the pharmacovigilance eating disorder signal — explains WHY the signal exists via subtype-specific GLP-1R mechanism +EXTRACTION HINT: Focus on the BED-protective vs. AN-harmful mechanism distinction; extractor should NOT collapse eating disorders into a single category diff --git a/inbox/queue/2025-12-01-who-glp1-obesity-guideline-eating-disorder-gap.md b/inbox/queue/2025-12-01-who-glp1-obesity-guideline-eating-disorder-gap.md new file mode 100644 index 000000000..39c611b81 --- /dev/null +++ b/inbox/queue/2025-12-01-who-glp1-obesity-guideline-eating-disorder-gap.md @@ -0,0 +1,47 @@ +--- +type: source +title: "WHO Issues Global Guideline on the Use of GLP-1 Medicines in Treating Obesity — Notable Absence of Eating Disorder Risk Guidance" +author: "World Health Organization" +url: https://www.who.int/news/item/01-12-2025-who-issues-global-guideline-on-the-use-of-glp-1-medicines-in-treating-obesity +date: 2025-12-01 +domain: health +secondary_domains: [] +format: official-guidance +status: unprocessed +priority: medium +tags: [glp1, who, guideline, obesity, global, eating-disorders, regulatory-gap] +intake_tier: research-task +--- + +## Content + +WHO global guideline issued December 1, 2025, recommending GLP-1 therapies (semaglutide and two other agents) for long-term treatment of obesity in adults. + +Exclusion: Pregnant women (only explicit population exclusion noted in news release). + +Eating disorder risk: NOT mentioned in the guideline news release. No specific contraindications for eating disorder history, no screening requirements, no psychiatric adverse event profile discussed. + +Conditional recommendation rationale: "limited data on their long-term efficacy and safety" — but eating disorders not specifically named among the safety concerns requiring more data. + +Additional safety note: Concern about "falsified and substandard medical products" posing threats to patient safety — requires "regulated distribution and prescription by qualified health care providers." + +## Agent Notes +**Why this matters:** This is the MOST IMPORTANT regulatory gap finding in today's session. The WHO — the global health authority — issued a broad recommendation for GLP-1 in obesity treatment in December 2025, at least 18 months AFTER the VigiBase eating disorder signal was published and without any eating disorder screening requirement or contraindication. This is not a gap in evidence — the signal existed. It's a gap in regulatory response. + +**What surprised me:** The contrast between (a) WHO issuing a global obesity guideline in December 2025 that makes no mention of ED risk, and (b) the eating disorder pharmacovigilance signal being documented in the literature throughout 2024-2025. The FDA/EMA January 2026 review focused on suicidality (and found no causal link) but apparently similarly did not issue eating disorder-specific guidance. This creates a world where 43M+ Americans are on GLP-1s, the global health authority has just recommended broad adoption, and no formal screening requirement for eating disorder history exists. + +**What I expected but didn't find:** Any WHO mention of eating disorder history as a contraindication or risk factor. Compared to the suicidality signal (which received EMA/FDA formal review), the eating disorder signal has received essentially no regulatory response despite higher magnitude (aROR 4.17-6.80 vs 1.45 for suicidality). + +**KB connections:** +- [[healthcare AI regulation needs blank-sheet redesign because the FDA drug-and-device model built for static products cannot govern continuously learning software]] — parallel regulatory response failure +- [[SDOH interventions show strong ROI but adoption stalls because Z-code documentation remains below 3 percent]] — same pattern: known intervention (ED screening) not operationalized +- [[CMS is creating AI-specific reimbursement codes]] — regulatory innovation for AI; regulatory silence for GLP-1 ED risk + +**Extraction hints:** Key finding: "The WHO December 2025 global GLP-1 obesity guideline contains no eating disorder screening requirement or contraindication despite the pharmacovigilance eating disorder signal (aROR 4.17-6.80) predating the guideline by at least 18 months." This is a regulatory response gap claim — challengeable, specific, and documentable. + +**Context:** News release, not the full guideline document. The full guideline may contain more detail — but the absence from the news release summary suggests it's not a prominent recommendation. + +## Curator Notes (structured handoff for extractor) +PRIMARY CONNECTION: [[healthcare AI regulation needs blank-sheet redesign because the FDA drug-and-device model built for static products cannot govern continuously learning software]] +WHY ARCHIVED: Documents the asymmetry between signal magnitude (highest psychiatric signal) and regulatory response (none) — this is the structural governance gap that makes the eating disorder risk a Vida-domain systemic claim, not just a clinical risk note +EXTRACTION HINT: Frame the claim as: "The regulatory response to GLP-1 eating disorder risk (none) is disproportionate to the pharmacovigilance signal magnitude (highest psychiatric signal, class effect), indicating institutional failure to translate pharmacovigilance findings into prescribing guidance." diff --git a/inbox/queue/2025-xx-frontiers-glp1-metabolic-nutritional-adverse-events-pharmacovigilance.md b/inbox/queue/2025-xx-frontiers-glp1-metabolic-nutritional-adverse-events-pharmacovigilance.md new file mode 100644 index 000000000..4245b9337 --- /dev/null +++ b/inbox/queue/2025-xx-frontiers-glp1-metabolic-nutritional-adverse-events-pharmacovigilance.md @@ -0,0 +1,51 @@ +--- +type: source +title: "Pharmacovigilance Study of GLP-1 Receptor Agonists for Metabolic and Nutritional Adverse Events" +author: "Frontiers in Pharmacology" +url: https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2024.1416985/full +date: 2024-01-01 +domain: health +secondary_domains: [] +format: paper +status: unprocessed +priority: low +tags: [glp1, pharmacovigilance, metabolic, nutritional, faers, adverse-events, dehydration] +intake_tier: research-task +--- + +## Content + +Pharmacovigilance analysis of GLP-1 receptor agonists for metabolic and nutritional adverse events across seven agents using FAERS data. + +Key signal counts: +- Semaglutide: 20 signals; Dulaglutide: 22 signals; Liraglutide: 16 signals; Exenatide: 12; Tirzepatide: 11; Lixisenatide: 2; Albiglutide: 1 + +ROR values for metabolism/nutrition disorders: +- Semaglutide: ROR 3.34; Liraglutide: ROR 2.78; Exenatide: ROR 2.15 + +Dehydration as most serious metabolic adverse event: +- Semaglutide: 370 cases (25.10% of serious reports) +- Dulaglutide: 434 cases (20.90%) +- Liraglutide: 318 cases (23.93%) +- Tirzepatide: 70 cases (32.86%) + +Authors' conclusion: "GLP-1 RAs have considerable potential for the treatment of eating disorders" despite safety concerns, given appetite-suppressing mechanisms. + +## Agent Notes +**Why this matters:** Dehydration emerging as the dominant serious metabolic adverse event is relevant to the eating disorder risk story — dehydration + electrolyte disruption is one of the primary medical complications of both bulimia nervosa (purging) and anorexia nervosa (restricted intake). If GLP-1 GI side effects (nausea, vomiting, diarrhea) induce dehydration, and this is happening in patients with undetected purging behaviors, the harm pathway is amplified. + +**What surprised me:** The authors' conclusion that GLP-1s "have considerable potential for the treatment of eating disorders" despite documenting significant adverse events — this optimistic framing in the face of pharmacovigilance signals is itself a data point about the field's willingness to interpret ambiguous evidence favorably. + +**What I expected but didn't find:** Any eating disorder-specific adverse event breakdown in a metabolic/nutritional focus paper. The eating disorder signal is covered in the psychiatric pharmacovigilance literature, not here. + +**KB connections:** +- [[continuous health monitoring is converging on a multi-layer sensor stack]] — dehydration is one of the first physiological changes that continuous monitoring (CGMs, electrolyte patches) could detect in GLP-1 users at ED risk + +**Extraction hints:** Lower priority than other ED sources — useful for the dehydration-ED risk interaction but not primary evidence for the eating disorder signal itself. Recommend citing alongside NEDA/ANAD guidance on hydration monitoring. + +**Context:** FAERS pharmacovigilance, lower precision than VigiBase multinational study. Primarily useful for context on the metabolic adverse event profile, not the psychiatric/eating disorder signal. + +## Curator Notes (structured handoff for extractor) +PRIMARY CONNECTION: [[continuous health monitoring is converging on a multi-layer sensor stack of ambient wearables periodic patches and environmental sensors processed through AI middleware]] +WHY ARCHIVED: The dehydration finding creates a connection between GLP-1 adverse events and the continuous monitoring space — dehydration + electrolyte monitoring as a GLP-1 safety use case +EXTRACTION HINT: Secondary source for context; cite primarily for dehydration prevalence data, not eating disorder risk specifically. diff --git a/inbox/queue/2025-xx-national-geographic-glp1-eating-disorder-clinical-concerns.md b/inbox/queue/2025-xx-national-geographic-glp1-eating-disorder-clinical-concerns.md new file mode 100644 index 000000000..cfc184647 --- /dev/null +++ b/inbox/queue/2025-xx-national-geographic-glp1-eating-disorder-clinical-concerns.md @@ -0,0 +1,51 @@ +--- +type: source +title: "Doctors Are Worried About Prescribing GLP-1s to Certain Patients" +author: "National Geographic Health" +url: https://www.nationalgeographic.com/health/article/glp-1-drugs-eating-disorder-risks +date: 2025-01-01 +domain: health +secondary_domains: [] +format: article +status: unprocessed +priority: medium +tags: [glp1, eating-disorders, clinical-concerns, prescribers, anorexia, atypical-anorexia, misuse, online-access] +intake_tier: research-task +--- + +## Content + +National Geographic health article documenting clinician concerns about GLP-1 prescribing in eating disorder-vulnerable populations. + +Key clinical findings: +- Case report 2025: 39-year-old patient with anorexia taking a GLP-1 drug despite having an extremely low BMI of 16 — acquired online by misrepresenting their weight +- Some clinicians now state they "won't give a GLP-1 if they discover a patient had a period of anorexia, or even atypical anorexia" — informal contraindication emerging in specialist practice before any formal guideline +- A 2023 analysis of FDA adverse-event reports found misuse reports for semaglutide were FOUR TIMES higher than for other GLP-1 drugs at the time +- Semaglutide associated with remarkably higher levels of abuse, intentional product use issues, and use without a prescription + +Key research gap: "To date, no clinical evidence links GLP-1RA use to the onset or worsening of anorexia nervosa" — the mechanistic concern is real but causality unproven in clinical trials + +BED-positive evidence: Some studies found decreased binge eating episodes for BED and bulimia nervosa — but small samples (3-6 months only) + +Screening: Most patients receive NO evaluation for eating disorders before GLP-1 prescription. Psychologist Robyn Pashby (also quoted in NPR article) again: "hold two truths" framing. + +## Agent Notes +**Why this matters:** The FOUR TIMES higher misuse rate for semaglutide vs. other GLP-1 drugs is striking — semaglutide is the highest-profile, most socially amplified agent (Ozempic, Wegovy branding). This suggests the social narrative/media attention around semaglutide specifically creates a misuse signal that is partially a Clay-domain problem: the "Ozempic" cultural narrative drives both (a) high prescribing volume and (b) high-risk off-label use without screening. + +**What surprised me:** The BMI 16 case where a patient acquired the drug online by lying about their weight — this documents that the supply chain for GLP-1s has no clinical gate at all for at-risk patients. BMI 16 is severe anorexia territory where appetite suppression is potentially fatal. The clinical gate should be obvious (screen for low weight, screen for eating disorder) but clearly isn't operational even in the extreme case. + +**What I expected but didn't find:** Any pharmaceutical company (Novo Nordisk, Eli Lilly) communication about eating disorder risk monitoring in their post-marketing commitments. + +**KB connections:** +- [[Big Food companies engineer addictive products by hacking evolutionary reward pathways]] — the "Ozempic" brand narrative creates a parallel to food marketing: aspirational weight loss framing overrides safety awareness +- [[consumer willingness to pay out of pocket for AI-enhanced care is outpacing reimbursement]] — same dynamic for GLP-1s: OOP consumer demand bypasses clinical gatekeeping + +**Extraction hints:** The semaglutide misuse rate (4x higher than other GLP-1s) is a specific, citable data point that connects the pharmacovigilance signal to the social/narrative amplification dynamic. Claim candidate: "Semaglutide's higher misuse rate relative to other GLP-1 receptor agonists reflects cultural narrative amplification ('Ozempic') rather than pharmacological superiority, creating a population-selection artifact in eating disorder pharmacovigilance signals." +**flagged_for_clay**: The "Ozempic" cultural narrative as a health risk vector — the brand story creates misuse behaviors. This is the clearest health-narrative intersection so far. + +**Context:** Journalism with expert quotes. Not primary evidence but documents clinical practice evolution (informal contraindications emerging before formal guidelines). + +## Curator Notes (structured handoff for extractor) +PRIMARY CONNECTION: [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]] +WHY ARCHIVED: The semaglutide misuse rate (4x higher) and the BMI 16 case document the online access problem specifically — this is the supply chain governance failure, separate from the prescribing guidance failure +EXTRACTION HINT: Focus on the 4x misuse differential and the BMI 16 online acquisition case — these document that online supply chains have no clinical gate whatsoever diff --git a/inbox/queue/2025-xx-neda-anad-glp1-eating-disorders-clinical-guidance.md b/inbox/queue/2025-xx-neda-anad-glp1-eating-disorders-clinical-guidance.md new file mode 100644 index 000000000..ef00f0b71 --- /dev/null +++ b/inbox/queue/2025-xx-neda-anad-glp1-eating-disorders-clinical-guidance.md @@ -0,0 +1,68 @@ +--- +type: source +title: "GLP-1 Medications and Eating Disorders: NEDA and ANAD Clinical Guidance" +author: "National Eating Disorders Association (NEDA) and National Association of Anorexia Nervosa and Associated Disorders (ANAD)" +url: https://www.nationaleatingdisorders.org/glp-and-eating-disorders/ +date: 2025-01-01 +domain: health +secondary_domains: [] +format: clinical-guidance +status: unprocessed +priority: medium +tags: [glp1, eating-disorders, neda, anad, clinical-guidance, screening, contraindications, monitoring] +intake_tier: research-task +--- + +## Content + +Consolidated guidance from two leading eating disorder advocacy/clinical organizations (NEDA and ANAD) on GLP-1 medications in the context of eating disorders. + +**Who should avoid GLP-1 medications (NEDA):** +- Current or past anorexia nervosa or atypical anorexia nervosa +- Active restrictive behaviors, bingeing, or purging +- Severe body image issues or unstable recovery +- Lack of appropriate monitoring or multidisciplinary support +- Signs the medication is being sought solely for weight loss + +**No FDA warnings** for eating disorder populations — clinical guidance is professional society recommendation only. + +**Required care team (ANAD):** +- Physician versed in GLP-1s and eating disorders +- Therapist experienced with both GLP-1s and ED treatment +- Dietitian familiar with this medication class and recovery nutrition + +**Monitoring requirements (ANAD):** +- Hydration and electrolyte levels (vomiting + GI side effects pose serious risk) +- Emergence of restrictive eating behaviors +- Weight loss rate and magnitude +- Eating disorder symptom changes via standardized measures + +**Documented risks:** +- GI side effects (nausea, vomiting, diarrhea, gastroparesis) "can trigger or worsen purging behaviors" in vulnerable individuals +- Appetite suppression may reinforce restrictive eating patterns +- Disruption of hunger/satiety awareness critical to recovery +- Potential weight cycling + psychological effects upon discontinuation +- ~2/3 of weight loss returns within one year if medication stops (ANAD note — consistent with continuous-delivery dependency pattern) + +**Research basis for BED:** Mixed results with very small sample sizes; only 3-6 month follow-ups; one RCT found "patients didn't experience any change in their eating disorder behaviors" + +## Agent Notes +**Why this matters:** This documents the gold-standard clinical guidance from the two organizations most focused on eating disorder treatment. The fact that their guidance is RECOMMENDATION-ONLY (not regulatory requirement) while describing a tri-specialist care team as essential before prescribing captures the implementation gap perfectly. Most GLP-1 prescriptions come from primary care physicians who have none of these three specialists available. + +**What surprised me:** The ANAD finding that GI side effects (nausea, vomiting) "can trigger or worsen purging behaviors" in vulnerable individuals — this is a mechanism I hadn't considered. The drug's most common adverse effects (GI effects experienced by ~40% of users) overlap precisely with purging behaviors in bulimia nervosa. This is a direct pharmacological pathway to harm, not just an indirect psychological reinforcement. + +**What I expected but didn't find:** Any data on how many patients currently taking GLP-1s have disclosed eating disorder histories to their prescribers. Given the stigma around ED disclosure and the lack of systematic screening, this number is almost certainly very low. + +**KB connections:** +- [[medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate]] — the ED risk is primarily behavioral/psychological, not pharmacological, but pharmacology creates the trigger +- [[the mental health supply gap is widening not closing]] — the recommended tri-specialist care team (physician + therapist + dietitian) is even more supply-constrained for ED specialists than general mental health +- [[prescription digital therapeutics failed as a business model]] — DTx for ED treatment also has a weak evidence base; no proven scalable solution + +**Extraction hints:** Key structural claim: "GLP-1 prescribing guidelines from eating disorder specialists require a tri-specialist care team (physician + ED therapist + dietitian) but this care team structure is unavailable in primary care settings where most GLP-1 prescriptions originate." This operationalizes the screening gap into a structural capacity gap. + +**Context:** Professional society guidance, not regulatory requirement. NEDA and ANAD do not have prescribing authority — their guidance creates no legal obligation. But they represent the authoritative clinical voice in this space. + +## Curator Notes (structured handoff for extractor) +PRIMARY CONNECTION: [[the mental health supply gap is widening not closing because demand outpaces workforce growth and technology primarily serves the already-served rather than expanding access]] +WHY ARCHIVED: The tri-specialist recommendation vs. primary care prescribing reality creates a structural capacity gap — this is a claim about healthcare system fragmentation, not just individual risk +EXTRACTION HINT: Focus on the structural implementation gap: who issues the guidance vs. who prescribes the drug (specialists vs. PCPs). The gap between recommended practice and actual prescribing workflow is the claim. diff --git a/inbox/queue/2025-xx-pmc-glp1-eating-disorders-double-edged-sword.md b/inbox/queue/2025-xx-pmc-glp1-eating-disorders-double-edged-sword.md new file mode 100644 index 000000000..125395bfc --- /dev/null +++ b/inbox/queue/2025-xx-pmc-glp1-eating-disorders-double-edged-sword.md @@ -0,0 +1,49 @@ +--- +type: source +title: "GLP-1 Receptor Agonists in the Context of Eating Disorders: A Promising Therapeutic Option or a Double-Edged Sword?" +author: "PMC / Journal of Clinical Medicine (multiple authors)" +url: https://pmc.ncbi.nlm.nih.gov/articles/PMC12072339/ +date: 2025-01-01 +domain: health +secondary_domains: [] +format: paper +status: unprocessed +priority: high +tags: [glp1, eating-disorders, anorexia, binge-eating, pharmacovigilance, adolescents, misuse] +intake_tier: research-task +--- + +## Content + +Systematic narrative review examining the dual role of GLP-1 receptor agonists in eating disorders — both therapeutic potential (BED) and risk (restrictive EDs). Published in Journal of Clinical Medicine, archived on PMC. + +Key findings: +- Critical paradox: GLP-1 RAs show promise for BED treatment while their widespread popularity raises concerns about harm in restrictive eating disorder populations +- Social media promotes GLP-1s "for esthetic purposes" as miracle weight-loss treatments, which could trigger restrictive eating behaviors in vulnerable individuals +- At-risk populations: adolescents (EDs peak during adolescence; social media use high), patients without medical supervision obtaining GLP-1s for cosmetic purposes, individuals with prior ED history/predisposition +- Mechanisms: (1) BED-beneficial: activates satiety centers + reward pathways → reduces binge episodes; (2) Restrictive ED-harmful: enhanced satiety + appetite suppression could paradoxically reinforce restrictive eating if misused without psychological support +- Case evidence: 2025 case — woman with childhood anorexia prescribed tirzepatide for metabolic indications → reignited restrictive patterns + overexercise + secret continued dosing after physician stopped prescription + +Regulatory gap: +- "No definitive evidence of the causal relationship between use of GLP-1 RAs in humans and development of psychiatric adverse events" regarding eating disorders specifically +- Calls for: pre/post-treatment psychological assessment, screening for high-risk ED patients before initiating, monitoring for GLP-1 misuse symptoms, longer-term follow-up studies (up to 5 years) to detect delayed ED symptom onset + +## Agent Notes +**Why this matters:** Provides the clearest framing of the "double-edged sword" paradox — the same pharmacological class that may treat BED (which accounts for the largest share of eating disorder prevalence) may harm the restrictive subtypes (AN) that carry the highest mortality risk. The mortality asymmetry makes this critical: BED mortality is low, AN mortality is 5-10% (highest of any psychiatric disorder). + +**What surprised me:** The explicit identification of SOCIAL MEDIA as a mechanism through which GLP-1 misuse reaches eating-disorder-vulnerable populations — this is a Clay (entertainment/narrative) cross-domain connection. The cultural framing of GLP-1s as "miracle weight loss" is itself a health risk vector. + +**What I expected but didn't find:** Quantified evidence of how often GLP-1 misuse for cosmetic weight loss leads to eating disorder onset or relapse — the paper identifies the concern but has no incidence data. + +**KB connections:** +- [[Big Food companies engineer addictive products by hacking evolutionary reward pathways]] — parallel structure: pharmaceutical industry creating weight-loss tools that interact with the same reward pathways as food-engineered products +- [[modernization dismantles family and community structures]] — the social isolation + social media combination as eating disorder risk amplifier + +**Extraction hints:** Key claim: "GLP-1 misuse for cosmetic weight loss, facilitated by social media and online access without screening, is a novel pathway for eating disorder onset or relapse." Secondary claim: "Adolescents are the highest-risk population for GLP-1-induced eating disorder harm because ED prevalence peaks during adolescence and social media exposure is highest." + +**Context:** Narrative review — useful for framing and identifying research gaps, but not primary evidence. + +## Curator Notes (structured handoff for extractor) +PRIMARY CONNECTION: [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]] +WHY ARCHIVED: Frames the eating disorder risk as a population-selection and access-governance problem — useful for the structural misalignment argument (GLP-1s widely available without ED screening, creating predictable harm in vulnerable populations) +EXTRACTION HINT: Focus on the social media / cosmetic misuse pathway — this is the behavioral mechanism that links to Clay's domain. Also flag the adolescent population risk for potential youth health claim. diff --git a/inbox/queue/2025-xx-pmc-glp1-psychiatric-disproportionality-faers-cvarod-daen.md b/inbox/queue/2025-xx-pmc-glp1-psychiatric-disproportionality-faers-cvarod-daen.md new file mode 100644 index 000000000..f13d16497 --- /dev/null +++ b/inbox/queue/2025-xx-pmc-glp1-psychiatric-disproportionality-faers-cvarod-daen.md @@ -0,0 +1,48 @@ +--- +type: source +title: "Psychiatric Adverse Events Linked to GLP-1 Analogues: A Disproportionality Analysis in American, Canadian and Australian Adverse Event Databases" +author: "PMC (multiple authors)" +url: https://pmc.ncbi.nlm.nih.gov/articles/PMC12630159/ +date: 2025-01-01 +domain: health +secondary_domains: [] +format: paper +status: unprocessed +priority: medium +tags: [glp1, pharmacovigilance, eating-disorders, faers, disproportionality, psychiatric-adverse-events, cross-national] +intake_tier: research-task +--- + +## Content + +Cross-national pharmacovigilance disproportionality analysis using three national adverse event databases: FAERS (US), Canada Vigilance Adverse Reaction Online Database (CVAROD), and Database of Adverse Event Notifications (DAEN, Australia). + +Key findings on eating disorders: +- Dulaglutide in FAERS: ROR = 1.47 (95%CI 1.26-1.71) +- Dulaglutide in DAEN (Australia): ROR = 17.66 (95%CI 2.45-127.37) — extremely elevated +- Tirzepatide in FAERS: ROR = 1.58 (95%CI 1.14-2.20) +- Note: Lower values than VigiBase study — reflects different database populations, denominator calculations, and the fact that this is US/CA/AU only vs. global VigiBase + +Indication bias explicitly acknowledged: "The databases used in this study did not contain information on any pre-existing psychiatric conditions in patients reporting AEs" — researchers could not "distinguish between a medicine-induced reaction and an event related to a patient's ongoing health issues" + +Causality conclusion: Researchers "cannot determine a causal relationship between medication use and AEs" — results should be "interpreted with caution and supplemented with clinical studies to confirm associations" + +## Agent Notes +**Why this matters:** Confirms the eating disorder signal across US, Canadian, and Australian databases — the signal isn't US-specific or FAERS-specific. The Australian DAEN result (ROR 17.66 for dulaglutide) is particularly high, suggesting the signal may be even stronger in populations where dulaglutide has higher relative prescribing share. The cross-national consistency increases biological plausibility. + +**What surprised me:** The ROR values here (1.47-1.58) are MUCH lower than the VigiBase aROR (4.17-6.80). This discrepancy is methodologically significant: VigiBase uses adjusted analysis (aROR controls for co-reported adverse events) while this study may not. The VigiBase analysis is the more reliable estimate — but the discrepancy between studies is itself a finding that an extractor should note. + +**What I expected but didn't find:** CVAROD (Canadian) results for eating disorders — the paper either didn't find a significant signal there or the abstract/summary I accessed didn't report it. + +**KB connections:** +- [[AI diagnostic triage achieves 97 percent sensitivity]] — parallel: pharmacovigilance databases have the same "signal vs. noise" sensitivity-specificity tradeoff +- [[healthcare AI regulation needs blank-sheet redesign]] — pharmacovigilance methodology also needs redesign for medication classes with behavioral effects + +**Extraction hints:** Useful as CORROBORATING evidence for the VigiBase signal across additional databases. The Australian DAEN outlier (ROR 17.66) deserves specific mention — possible explanation is small denominator, different population, or higher awareness/reporting in Australia. NOT sufficient as a standalone source for the eating disorder claim — use alongside VigiBase as supporting evidence. + +**Context:** This is a methodologically weaker study than the VigiBase analysis but provides geographic breadth. The indication bias limitation is shared by all pharmacovigilance databases. + +## Curator Notes (structured handoff for extractor) +PRIMARY CONNECTION: [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]] +WHY ARCHIVED: Corroborating cross-national evidence for the eating disorder pharmacovigilance signal — extractor should use as secondary evidence, not primary +EXTRACTION HINT: Flag the discrepancy between this study's ROR (1.47-1.58) and VigiBase's aROR (4.17-6.80) in any claims that cite both — the methodological difference matters. diff --git a/inbox/queue/2025-xx-vigibase-glp1-psychiatric-adverse-events-eating-disorders.md b/inbox/queue/2025-xx-vigibase-glp1-psychiatric-adverse-events-eating-disorders.md new file mode 100644 index 000000000..169994eb0 --- /dev/null +++ b/inbox/queue/2025-xx-vigibase-glp1-psychiatric-adverse-events-eating-disorders.md @@ -0,0 +1,47 @@ +--- +type: source +title: "Psychiatric and Psychological Adverse Effects Associated with Dulaglutide, Semaglutide, and Liraglutide: A VigiBase Study" +author: "ScienceDirect / Clinical Nutrition (multiple authors)" +url: https://pubmed.ncbi.nlm.nih.gov/40617160/ +date: 2025-01-01 +domain: health +secondary_domains: [] +format: paper +status: unprocessed +priority: high +tags: [glp1, pharmacovigilance, eating-disorders, vigibase, psychiatric-adverse-events, semaglutide, class-effect] +intake_tier: research-task +--- + +## Content + +Primary pharmacovigilance study using VigiBase® (multinational WHO adverse drug reaction database) analyzing 2,061,901 reports through December 1, 2024 for three GLP-1 receptor agonists: dulaglutide, semaglutide, and liraglutide. + +Key findings: +- EATING DISORDERS: significant signal across ALL THREE GLP-1 RAs; aRORs between 4.17 and 6.80 — highest magnitude psychiatric signal in the study +- Semaglutide additional signals: depressed mood disorders (aROR 1.70, 95%CI 1.57-1.84); suicidality (aROR 1.45, 95%CI 1.29-1.63); anxiety (aROR 1.26, 95%CI 1.18-1.35) +- Sensitivity analysis: no signals before June 4, 2021 (Wegovy obesity approval date) — suggests the eating disorder signal emerged SPECIFICALLY in the obesity treatment population, not in the prior metabolic population +- The pre-Wegovy absence of signal aligns with RCT data from metabolic trials (no eating disorder signal in T2D populations) +- The post-Wegovy emergence implies the risk is specific to: (a) patients seeking GLP-1 for weight management specifically, and/or (b) the higher weight-loss doses used in obesity treatment vs. metabolic indications + +Key limitation explicitly stated: the database did not contain information on pre-existing psychiatric conditions in patients reporting AEs — researchers could not distinguish medicine-induced reactions from events related to patients' ongoing health conditions (i.e., cannot rule out indication bias). + +## Agent Notes +**Why this matters:** This is the PRIMARY quantitative evidence for the eating disorder signal. The class-effect finding (all three agents, not just semaglutide) is the most important detail — it suggests the signal is pharmacological, not drug-specific, which strengthens the mechanism hypothesis. The Wegovy cutoff finding is equally important: the signal is specific to the obesity treatment population, not metabolic patients, which either means (a) the higher doses create more risk, or (b) people with obesity/weight preoccupation are more ED-vulnerable, or (c) the obesity treatment population includes more people with undetected ED histories. + +**What surprised me:** That no signals appeared before June 4, 2021 — this is strong evidence that the signal is NOT explained by years of metabolic use (T2D, which began much earlier). The risk is specific to the obesity-treatment population and/or the higher weight-management doses. This is the most important piece of evidence for differentiating between indication bias and drug effect. + +**What I expected but didn't find:** Specific breakdown of the eating disorder signal by subtype (BED vs. AN vs. atypical AN). The aggregated eating disorder category prevents distinguishing whether GLP-1 is triggering restrictive EDs (theoretically harmful via appetite suppression) or BED (for which it may be therapeutic). The signal might be predominantly reported as BED events in people discovering they have improved — or predominantly restrictive events in people worsening. + +**KB connections:** +- [[human-in-the-loop clinical AI degrades to worse-than-AI-alone because physicians both de-skill from reliance and introduce errors]] — parallel: the automation of appetite suppression through pharmacology disrupts the biological feedback loop that maintains normal eating behavior +- [[AI scribes reached 92 percent provider adoption]] — GLP-1 prescription similarly reached mass adoption before safety signal was fully characterized + +**Extraction hints:** CRITICAL claim: "GLP-1 eating disorder pharmacovigilance signal (aROR 4.17-6.80) is a class effect that emerged specifically in the obesity treatment population after June 2021, not in the prior metabolic population, suggesting the risk is either dose-dependent or population-selection-dependent." This claim is specific, challengeable, and has clinical implications for prescribing criteria. + +**Context:** VigiBase is the WHO's multinational pharmacovigilance database — larger and more global than FAERS. aROR (adjusted Reporting Odds Ratio) controls for multiple adverse events in same reports. This is the most robust pharmacovigilance evidence available for this signal. + +## Curator Notes (structured handoff for extractor) +PRIMARY CONNECTION: [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]] +WHY ARCHIVED: The primary quantitative source for the eating disorder pharmacovigilance signal — all downstream claims about aROR values should cite this paper +EXTRACTION HINT: The June 2021 temporal boundary is the key evidentiary detail. Extractor should center the claim on this finding — it's what distinguishes this signal from general GLP-1 psychiatric risk. diff --git a/inbox/queue/2026-02-04-npr-glp1-eating-disorders-anorexia-unknown-risks.md b/inbox/queue/2026-02-04-npr-glp1-eating-disorders-anorexia-unknown-risks.md new file mode 100644 index 000000000..ddb0daed7 --- /dev/null +++ b/inbox/queue/2026-02-04-npr-glp1-eating-disorders-anorexia-unknown-risks.md @@ -0,0 +1,57 @@ +--- +type: source +title: "GLP-1 Obesity Drugs and Eating Disorders: The Risks Are Not Yet Well Understood" +author: "NPR Health" +url: https://www.npr.org/2026/02/04/nx-s1-5677633/glp-1-obesity-wegovy-zepbound-eating-disorders-anorexia-bulimia +date: 2026-02-04 +domain: health +secondary_domains: [] +format: article +status: unprocessed +priority: high +tags: [glp1, eating-disorders, anorexia, atypical-anorexia, screening-gaps, access, misuse] +intake_tier: research-task +--- + +## Content + +NPR health journalism piece (February 4, 2026) examining what is and isn't known about GLP-1 drugs and eating disorder risk. Key voices: Robyn Pashby (psychologist), Samantha DeCaro (clinician). + +Key facts: +- Nearly 10% of Americans meet clinical eating disorder criteria at some point +- GLP-1s are "more powerful and wholly different from earlier weight-loss drugs" — more concerning because they suppress natural hunger cues more profoundly +- Very little known about how GLP-1 use or misuse affects people who binge or restrict food +- Most patients receive NO evaluation for eating disorders before GLP-1 prescription +- Drugs are "easy to obtain online, with little screening" + +High-risk populations identified: +- Atypical anorexics (restrict food but maintain normal weight — "at high risk of being harmed" because doctors may not recognize the condition) +- Online purchasers with no clinical screening +- People with body dysmorphia or weight-related trauma histories + +Clinical framing: +- Pashby: "Hold two truths: That GLP-1s are legitimate evidence-based treatments for obesity, but that they also sit inside our culture, which has intense weight pressure, weight stigma and eating disorder risk" +- DeCaro: Weight loss alone rarely addresses underlying psychological drivers of eating disorders, which typically involve "emotional, relational, and biological drivers" + +Regulatory/policy: ZERO regulatory actions or FDA guidance found for eating disorder risk specifically. No national guidelines requiring ED screening before prescription — only recommended by some professional groups. + +## Agent Notes +**Why this matters:** This is the most important real-world evidence: screening happens essentially never. The pharmacovigilance signal (aROR 4.17-6.80) exists in a context where no structural intervention (regulatory requirement, screening mandate, prescriber training) is reducing exposure in vulnerable populations. This is a pure structural misalignment story. + +**What surprised me:** The "atypical anorexia" population as the highest-risk and most invisible group — they maintain normal weight (so they don't look anorexic), which means both patients and prescribers may not recognize they're contraindicated for GLP-1s. Given that GLP-1s are now prescribed primarily for weight management, the typical candidate appearance overlaps with atypical AN presentation. + +**What I expected but didn't find:** Any concrete estimate of how many people with ED histories are currently taking GLP-1s. Given 10% lifetime ED prevalence and 43M+ Americans on GLP-1s, the theoretical overlap is enormous but unquantified. + +**KB connections:** +- [[value-based care transitions stall at the payment boundary]] — parallel: screening for ED before GLP-1 prescribing stalls at the "no reimbursement for screening time" boundary +- [[SDOH interventions show strong ROI but adoption stalls because Z-code documentation remains below 3 percent]] — same structural problem: screening that produces better outcomes but that no system rewards doing +- [[the mental health supply gap is widening not closing]] — ED specialty care is even more supply-constrained than general mental health + +**Extraction hints:** Claim: "GLP-1 eating disorder screening is recommended but essentially never practiced because no regulatory body mandates it and no reimbursement exists for the time required." This is a structural claim about the prescribing workflow, not just a risk signal. + +**Context:** Journalism, not clinical evidence — but valuable for documenting the structural screening gap at the primary care level. + +## Curator Notes (structured handoff for extractor) +PRIMARY CONNECTION: [[SDOH interventions show strong ROI but adoption stalls because Z-code documentation remains below 3 percent and no operational infrastructure connects screening to action]] +WHY ARCHIVED: Documents the structural gap between pharmacovigilance evidence (signal exists) and clinical practice (no screening) — mirrors the SDOH implementation gap pattern +EXTRACTION HINT: Frame as a structural governance claim, not just a risk signal. The claim is about the mismatch between signal magnitude and regulatory response, not just about the risk itself.